HilleVax, Inc. (NASDAQ:HLVX) Shares Sold by State Street Corp

State Street Corp reduced its stake in HilleVax, Inc. (NASDAQ:HLVX) by 1.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 585,795 shares of the company’s stock after selling 9,650 shares during the period. State Street Corp’s holdings in HilleVax were worth $1,031,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BML Capital Management LLC acquired a new position in shares of HilleVax in the 3rd quarter valued at $35,000. GSA Capital Partners LLP purchased a new position in shares of HilleVax during the third quarter worth about $126,000. Maven Securities LTD purchased a new position in shares of HilleVax during the second quarter worth about $217,000. Verition Fund Management LLC acquired a new stake in shares of HilleVax during the third quarter worth about $331,000. Finally, Algert Global LLC purchased a new stake in shares of HilleVax in the 2nd quarter valued at about $519,000. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Stock Up 0.5 %

NASDAQ:HLVX opened at $2.08 on Friday. The company has a market capitalization of $103.60 million, a PE ratio of -0.67 and a beta of 0.81. HilleVax, Inc. has a 52-week low of $1.55 and a 52-week high of $20.22. The stock’s 50 day moving average price is $1.91 and its 200 day moving average price is $3.08.

HilleVax (NASDAQ:HLVX) last announced its earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.10). As a group, sell-side analysts anticipate that HilleVax, Inc. will post -2.64 EPS for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.